IQ-AI Ltd unit Imaging Biometrics on Tuesday said a study concluded its imaging technology was successful in identifying tumours.

The subsidiary of the Jersey-based medical services firm noted the results of a study published by the American Journal of Neuroradiology.

The probe used Imaging Biometrics software, as well as other advanced imaging methods, to evaluate metastatic brain tumours previously treated with a very precise form of radiation therapy called stereotactic radiosurgery.

The aim was to determine if any imaging technology could reliably distinguish between progressive tumour and radiation necrosis (non-tumour) tissue.

Results found IB’s quantitative mapping method could distinguish between progressive tumour and non-tumour tissue. Other imaging methods could not.

Chief Executive of IQ-AI Trevor Brown commented: ‘This relevant and powerful study further validates our decision to develop IB Trax.’

IQ-AI Ltd’s shares were up 4.9% at 4.56 pence each in late in London on Tuesday.

Copyright 2022 Alliance News Limited. All Rights Reserved.